Preconditioning with levosimendan before implantation of left ventricular assist devices

Artificial Organs

Volumn 38, Issue 3, 2014, Pages 231-234

  Theiss, Hans D ^a   Grabmaier, Ulrich ^a   Kreissl, Nicole ^b   Hagl, Christian ^b   Steinbeck, Gerhard ^a   Sodian, Ralf ^b   Franz, Wolfgang M ^a   Kaczmarek, Ingo ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cardiac assist device; Heart transplantation; Levosimendan; Terminal heart failure

Indexed keywords

CARDIOLOGY; FIBER OPTIC SENSORS; HEART; PATIENT TREATMENT;

ASSIST DEVICE; CARDIAC ASSIST; CARDIAC ASSIST DEVICE; HEART FAILURE; HEART INSUFFICIENCIES; HEART TRANSPLANTATION; LEVOSIMENDAN; RIGHT VENTRICLE; SENSITISER; TERMINAL HEART FAILURE;

LEFT VENTRICULAR ASSIST DEVICES;

LEVOSIMENDAN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; DRUG SAFETY; ECHOCARDIOGRAPHY; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; FEMALE; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HUMAN; IMPLANTATION; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC PRECONDITIONING; LEFT VENTRICULAR ASSIST DEVICE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

CARDIAC ASSIST DEVICE; HEART TRANSPLANTATION; LEVOSIMENDAN; TERMINAL HEART FAILURE;

AGED; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; PYRIDAZINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896725544     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12150     Document Type: Article

References (10)

1. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-1866.
2. Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994;269:28584-28590.
3. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002;40:465-471.
4. Greif M, Zwermann L, Reithmann C, Weis M. Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction. Acute Card Care 2008;10:185-190.
5. Weis F, Beiras-Fernandez A, Kaczmarek I, et al. Levosimendan: a new therapeutic option in the treatment of primary graft dysfunction after heart transplantation. J Heart Lung Transplant 2009;28:501-504.
6. Kirklin JK, Naftel DC, Stevenson LW, et al. INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant 2008;27:1065-1072.
7. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report: risk factor analysis from more than 6000 mechanical circulatory support patients. J Heart Lung Transplant 2013;32:141-156.
8. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
9. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-1432.
10. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-1891.